ABT vs NVS
ABT: A diversified global health care leader focused on diagnostic, medical device, nutritional, and pharmaceutical solutions. NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
Side-by-side fundamentals
| Metric | ABT | NVS | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $105.70 | $156.11 | |
| Market cap as of 2026-08-03 | $184.1B | $232.1B | |
| P/E as of 2026-08-03 | 34.02 | 22.53 | NVS lower |
| PEG as of 2026-08-03 | 3.63 | 3.66 | ABT lower |
| Net margin as of 2026-08-03 | +11.7% | +22.5% | NVS higher |
| Gross margin as of 2026-08-03 | +56.8% | +75.0% | NVS higher |
| Operating margin as of 2026-08-03 | +15.8% | +29.9% | NVS higher |
| ROE as of 2026-08-03 | +12.2% | +29.9% | NVS higher |
| ROA as of 2026-08-03 | +6.9% | +11.1% | NVS higher |
| Debt / equity as of 2026-08-03 | 0.65 | 1.18 | ABT lower |
| Revenue growth (YoY) as of 2026-08-03 | +8.1% | +3.3% | ABT higher |
| Revenue CAGR (3y) SEC XBRL | +0.5% | n/a | |
| Dividend yield as of 2026-08-03 | +2.4% | +2.9% | NVS higher |
| Dividend streak (yrs) SEC XBRL | 4 | n/a | |
| Beta as of 2026-08-03 | 0.16 | 1.17 | |
| 1-year return as of 2026-07-31 close | -16.2% | +32.6% | NVS higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.